Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
The chart shows the growth of an initial investment of $10,000 in Twist Bioscience Corporation Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Twist Bioscience Corporation Common Stock (TWST) has returned 58.24% so far this year and 49.66% over the past 12 months. Looking at the last ten years, TWST has achieved an annualized return of 14.47%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Twist Bioscience Corporation Common Stock (TWST) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 29.44% | 7.97% | 5.71% | 2.70% | ||||||||
| 2025 | 10.84% | -14.30% | 0.56% | -2.10% | -24.02% | 25.18% | -7.57% | -17.02% | 4.84% | 16.80% | -2.62% | 1.47% |
| 2024 | -9.55% | 19.82% | -12.83% | -8.71% | 35.07% | 15.60% | 15.57% | -21.86% | 6.76% | -9.57% | 20.27% | -5.34% |
| 2023 | 12.55% | -32.94% | -22.39% | -16.66% | 20.53% | 34.96% | 18.85% | -8.38% | -9.96% | -21.51% | 53.09% | 54.74% |
| 2022 | -23.43% | -7.57% | -11.25% | -41.74% | 18.11% | 2.52% | 23.98% | -7.04% | -10.47% | -9.16% | -19.58% | -13.26% |
| 2021 | 18.71% | -17.45% | -12.02% | 4.97% | -20.90% | 22.25% | -7.52% | -8.52% | -5.60% | 12.84% | -20.20% | -19.51% |
| 2020 | 17.06% | 23.47% | -1.48% | 10.73% | 18.11% | 18.84% | 23.16% | 23.40% | 8.62% | 0.04% | 46.20% | 25.66% |
| 2019 | 1.76% | -5.88% | 4.89% | 0.77% | 1.61% | 11.06% | 15.05% | -13.34% | -16.59% | -0.79% | -0.96% | -11.80% |
| 2018 | 7.69% | 77.58% | -14.83% |
The charts below present risk-adjusted performance metrics for Twist Bioscience Corporation Common Stock (TWST) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of TWST compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Twist Bioscience Corporation Common Stock volatility is 4.87%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 641.86M | 614.32M | 776.40M | 961.38M | 702.10M | 398.88M | 186.99M |
| Equity Attributable To Parent (USD) | 472.96M | 472.69M | 623.43M | 789.39M | 580.82M | 336.26M | 152.08M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - |
| Equity (USD) | 472.96M | 472.69M | 623.43M | 789.39M | 580.82M | 336.26M | 152.08M |
| Other Non-current Liabilities (USD) | - | - | - | - | - | 22.43M | - |
| Long-term Debt (USD) | - | - | - | - | - | 4.17M | 7.50M |
| Noncurrent Liabilities (USD) | 77.50M | 70.63M | 79.65M | 81.33M | 58.22M | 26.59M | 4.56M |
| Other Current Liabilities (USD) | 49.02M | 35.73M | 33.45M | 43.55M | 25.83M | 16.25M | 10.12M |
| Wages (USD) | 31.29M | 33.65M | 25.82M | 27.02M | 22.33M | 14.95M | 10.48M |
| Accounts Payable (USD) | 11.09M | 1.63M | 14.05M | 20.09M | 14.90M | 4.83M | 9.76M |
| Current Liabilities (USD) | 91.41M | 71.01M | 73.32M | 90.66M | 63.05M | 36.03M | 30.35M |
| Liabilities (USD) | 168.90M | 141.63M | 152.97M | 171.99M | 121.28M | 62.62M | 34.91M |
| Other Non-current Assets (USD) | 206.61M | 165.03M | 220.32M | 225.45M | 111.48M | 38.55M | 6.02M |
| Fixed Assets (USD) | 102.28M | 102.52M | 131.83M | 139.44M | 44.12M | 25.47M | 20.84M |
| Noncurrent Assets (USD) | 308.90M | 267.55M | 352.15M | 364.90M | 155.60M | 64.01M | 26.86M |
| Other Current Assets (USD) | 304.66M | 322.70M | 55.79M | 52.21M | 36.83M | 32.58M | 14.70M |
| Inventory (USD) | 28.31M | 24.08M | 32.06M | 39.31M | 31.80M | 12.29M | 7.33M |
| Cash (USD) | - | - | 336.40M | 504.97M | 477.86M | 290.00M | 138.11M |
| Current Assets (USD) | 332.97M | 346.78M | 424.26M | 596.48M | 546.50M | 334.87M | 160.14M |
| Assets (USD) | 641.86M | 614.32M | 776.40M | 961.38M | 702.10M | 398.88M | 186.99M |
ARK Invest's 2025 performance data shows the ARK Innovation ETF delivered a 35.5% return, significantly outperforming the S&P 500's 16.6% gain. Top performers included Robinhood Markets (+204%), Palantir Technologies (+135%), and AMD (+77%), while notable losers were The Trade Desk (-68%), Recursion Pharmaceuticals (-40%), and Twist Bioscience (-32%). ARK maintains conviction in underperforming positions based on long-term platform objectives.
The DNA computing market is projected to grow from $293.70 million in 2025 to $2.68 billion by 2032, with a 36.76% CAGR, driven by innovations in data storage, cryptography, and molecular computing technologies.
The global cell culture microcarriers market is projected to grow from USD 3.45 billion in 2025 to USD 7.2 billion by 2034, with an 8.54% CAGR, driven by advancements in biopharmaceuticals, cell therapies, and regenerative medicine research.
The DNA data storage market is expected to grow from $76 million in 2024 to $3,348 million by 2030, with a CAGR of 87.7%. The market is driven by increasing cybersecurity concerns and the need for secure, compact data storage solutions, particularly in healthcare and biotechnology sectors.
Twist Bioscience reported strong Q3 results with 18% revenue growth, achieving profitability through a one-time gain and improved operational efficiency. The company saw growth in Next Generation Sequencing and strategic product launches while managing slower Synthetic Biology segment performance.
The antibody discovery market is projected to grow at a 10% CAGR by 2032, driven by increasing chronic disease incidence, biologics adoption, and technological advancements in drug development.
The U.S. minimal residual disease testing market is projected to reach $2020 million by 2033, growing at a 9.38% CAGR, driven by rising cancer rates and advancements in precision medicine technologies like NGS and flow cytometry.
The global antibody discovery market size is anticipated to reach approximately USD 22,570 million by 2034, up from USD 9,570 million in 2025, expanding at a CAGR of 10% from 2025 to 2034. The growth is driven by the rising incidence of autoimmune and cancer diseases, rising preference for outsourcing in the pharmaceutical industry, and emerging disease targets.
The global RNA transcriptome profiling test market is expected to grow at a CAGR of 14.5% and reach a valuation of US$ 37,383.8 million by 2034, driven by increasing investments in biotechnology and genomics for the detection of chronic diseases.
The global gene panel market is projected to reach $11.75 billion by 2031, growing at a CAGR of 19.30% during the forecast period. The market growth is driven by advancements in genomic research, rising prevalence of genetic disorders, and growing awareness of genetic testing.
